Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Best Pract Res Clin Anaesthesiol ; 35(3): 293-306, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34511220

ABSTRACT

International hospitals and healthcare facilities are facing catastrophic financial challenges related to the COVID-19 pandemic. The American Hospital Association estimates a financial impact of $202.6 billion in lost revenue for America's hospitals and healthcare systems, or an average of $50.7 billion per month. Furthermore, it could cost low- and middle-income countries ~ US$52 billion (equivalent to US$8.60 per person) each four weeks to provide an effective healthcare response to COVID-19. In the setting of the largest daily COVID-19 new cases in the US, this burden will influence patient care, surgeries, and surgical outcomes. From a global economic standpoint, The World Bank projects that global growth is projected to shrink by almost 8% with poorer countries feeling most of the impact, and the United Nations projects that it will cost the global economy around 2 trillion dollars this year. Overall, a lack of preparedness was a major contributor to the struggles experienced by healthcare facilities around the world. Items such as personal protective equipment (PPE) for healthcare workers, hospital equipment, sanitizing supplies, toilet paper, and water were in short supply. These deficiencies were exposed by COVID-19 and have prompted healthcare organizations around the world to invent new essential plans for pandemic preparedness. In this paper, we will discuss the economic impact of COVID-19 on US and international hospitals, healthcare facilities, surgery, and surgical outcomes. In the future, the US and countries around the world will benefit from preparing a plan of action to use as a guide in the event of a disaster or pandemic.


Subject(s)
COVID-19/economics , COVID-19/epidemiology , Cost of Illness , Delivery of Health Care/economics , Global Health/economics , COVID-19/therapy , Delivery of Health Care/trends , Global Health/trends , Health Personnel/economics , Health Personnel/trends , Humans , Pandemics , Personal Protective Equipment/economics , Personal Protective Equipment/trends , United States/epidemiology
2.
Curr Pain Headache Rep ; 24(7): 37, 2020 Jun 06.
Article in English | MEDLINE | ID: mdl-32506251

ABSTRACT

PURPOSE OF REVIEW: Osteoarthritis (OA) is a highly prevalent cause of chronic hip pain, affecting 27% of adults aged over 45 years and 42% of adults aged over 75 years. Though OA has traditionally been described as a disorder of "wear-and-tear," recent studies have expanded on this understanding to include a possible inflammatory etiology as well, damage to articular cartilage produces debris in the joint that is phagocytosed by synovial cells which leads to inflammation. RECENT FINDINGS: Patients with OA of the hip frequently have decreased quality of life due to pain and limited mobility though additional comorbidities of diabetes, cardiovascular disease, poor sleep quality, and obesity have been correlated. Initial treatment with conservative medical management can provide effective symptomatic relief. Physical therapy and exercise are important components of a multimodal approach to osteoarthritic hip pain. Patients with persistent pain may benefit from minimally invasive therapeutic approaches prior to consideration of undergoing total hip arthroplasty. The objective of this review is to provide an update of current minimally invasive therapies for the treatment of pain stemming from hip osteoarthritis; these include intra-articular injection of medication, regenerative therapies, and radiofrequency ablation.


Subject(s)
Glucocorticoids/therapeutic use , Hip Joint/innervation , Mesenchymal Stem Cell Transplantation , Osteoarthritis, Hip/therapy , Pain Management/methods , Platelet-Rich Plasma , Radiofrequency Ablation , Acetylcholine Release Inhibitors/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bone Marrow Transplantation , Botulinum Toxins, Type A/therapeutic use , Conservative Treatment , Exercise Therapy , Femoral Nerve/surgery , Humans , Hyaluronic Acid/therapeutic use , Injections, Intra-Articular , Injections, Intramuscular , Obturator Nerve/surgery , Physical Therapy Modalities , Transplantation, Autologous , Treatment Outcome , Viscosupplements/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...